Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
B-RAF is the most frequently mutated protein kinase in human cancers. The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that the...